Automatic Synthesis and Screening System for Lipid Nanoparticles Sunscreen
Automatic Synthesis and Screening System for Lipid Nanoparticles Sunscreen
Accelerating formulation optimization for vaccine and pharmaceutical development.
To create the optimal LNP, it takes a tremendous amount of time and effort to examine and pursue formulation conditions. LNPs are nanoparticles composed of multiple lipids. Therefore, it is necessary to find the optimal conditions such as the mixing ratios, the ratio of lipids to payload, and the flow rates during mixing. Furthermore, we must also consider throughput issues. Sunscreen can produce up to 96 types of small LNPs within six hours, thus solving the previous throughput problems. This means that it is possible to explore a greater number of formulation condition investigations in a single day. • Fully automated execution of up to 96 types of condition investigations within six hours • 200 μL to 2 mL per experiment • Flow rate of 0.1 to 30 mL/min • Reusable microfluidic chips • Seamless scale-up through process and protocol optimization
Inquire About This Product
Related Videos
basic information
Throughput: Up to 96 formulations within 6 hours Total flow range: 0.1 to 30 mL/min (depending on the tip) Flow ratio (water to organic): 1:1 to 5:1 Standard sample volume range (when FRR is 3:1): 400 µL to 2 mL Minimum input volume (including dead volume): 105 µL Continuous mode capacity range: NA Inline dilution: Yes Standard particle size range: 40 to 200 nm (depending on the formulation) PDI: Less than 0.2 (depending on the formulation) Encapsulation efficiency: Over 90% (depending on the formulation)
Price range
Delivery Time
Applications/Examples of results
Pharmaceutical development Preparation of lipid nanoparticles
catalog(8)
Download All Catalogs

News about this product(14)
Company information
Unchained Labs is a company headquartered in Silicon Valley, California, that provides next-generation life science tools. - A lineup of automation devices for biopharmaceutical research, gene therapy, and organic synthesis - Founded in 2015 - Locations in California, New Jersey, Boston, the UK, Brussels, Germany, Shanghai, and Japan - Established a Japanese subsidiary in July 2017